Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.

ABSTRACT:

Purpose

Imatinib mesylate (Imatinib), clinically employed for chronic myeloid leukemia and gastrointestinal stromal tumors, is a selective inhibitor of the tyrosine kinases, c-abl, c-kit and PDGFRs. Due to the frequent expression of these genes in breast cancer cells, the clinical efficacy of Imatinib has recently been investigated in patients with advanced and metastatic breast cancer. Here, we have studied the effects of Imatinib on human MA-11 breast carcinoma cells, expressing both c-abl and PDGFRbeta, in vitro and in mouse xenografts.

Methods

The effects of Imatinib mesylate on the human MA-11 breast carcinoma cell line were studied in vitro and in xenografts.

Results

Daily intraperitoneal treatment with 60 mg/kg Imatinib for 9 days of athymic nude mice pre-impla

SUBMITTER: Rappa G 

PROVIDER: S-EPMC3273303 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature